drugset / Trial / NCT03933670
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
Phase 2
Recruiting
60 enrolled
University of California, San Francisco
National Cancer Institute (NCI) · collabNational Institute for Biomedical Imaging and Bioengineering (NIBIB) · collab
NaSingle-groupOpen-labelDiagnostic
Summary
This phase II trial studies the side how well hyperpolarized carbon C 13 pyruvate (HP C-13 pyruvate) magnetic resonance imaging (MRI) works in monitoring patients with prostate cancer on active surveillance who have not received treatment. Diagnostic procedures, such as MRI, may help visualize HP C-13 pyruvate uptake and breakdown in tumor cells.
Timeline
- Start
- 2018-07-18
- Primary completion
- 2027-12-31
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hyperpolarized 13C-Pyruvate | Diagnostic / imaging agent | — | Intravenous |